VahatiCor

Transforming cardiac care with the A-FLUX Reducer System, VahatiCor addresses coronary microvascular dysfunction, offering symptomatic relief.

[Cardiovascular Business @CardioBusiness]

Cardiologists detail world’s first implant of new device for ‘no-option’ chest pain patients @IUCPQ @VahatiCor #cardiology https://t.co/MySZ8f6YA1

[VahatiCor @VahatiCor]

VahatiCor's A-FLUX Reducer Therapy was selected for the EMA's Scientific Advice Pilot program! This aligns us with EMA to expedite CE-Mark approval. Exciting times ahead!
#Cardiology #coronary #AFLUX #CMD #interventionalcardiology #microvasculardysfunction
#EMA #cardioX

[EuroIntervention @EuroInterventio]

📌NEW ISSUE OUT📌

✅The 18th EBC consensus document;
✅Morphofunctional assessment in ACS patients;
✅OCT-guided PCI in STEMI patients;
✅A debate on bivalirudin;
✅The A-Flux − a selfexpanding coronary sinus reducer;
✅5-year outcomes of the ACURATE neo AS study;
and more

[VahatiCor @VahatiCor]

@MTomaniak @fra_giannini1 @aisnptk @PTKardio Thank you @MTomaniak for your excellent work!

[VahatiCor @VahatiCor]

@VahatiCor's A-FLUX Reducer System was featured on @EuroIntervention’s YouTube channel. Dr. Jean-Michel Paradis shared the first-in-human experience with our promising therapy.

📺 Watch the full interview: https://t.co/DvIJcG5TJm

#AFLUXReducer #microvasculardisease